Imclone Systems Inc
Article Abstract:
Imclone Systems Inc. and partner Bristol-myers Squibb have to obtain fast-track approval from the FDA for its ERBITUX and eventual release which could drive sales and earnings up. Equity has limited long-term capital-gains potential.
Publisher: Value Line Publishing, Inc.
Publication Name: The Value Line Investment Survey (Part 3 - Ratings & Reports)
Subject: Business, general
ISSN: 0042-2401
Year: 2003
Legal issues & crime, Government regulation (cont), Marketing procedures, Government regulation, Legal/Government Regulation, Laws, regulations and rules, Marketing, Licensing agreements, Licensing, certification and accreditation, Company marketing practices, United States. Food and Drug Administration, ImClone Systems Inc., Diagnostic reagents industry, IMCL, Erbitux (Medication)
Publication Name: The Value Line Investment Survey (Part 3 - Ratings & Reports)
Subject: Business, general
ISSN: 0042-2401
Year: 2003
User Contributions:
Comment about this article or add new information about this topic:
Exelixis Inc
Article Abstract:
Exelixis Inc. has developed products to be filed with the FDA and conducting clinical trials for 2 compounds this year. Issue is neutral for Timeliness but has appreciation potential out to 2006-2008 for venturesome investors.
Publisher: Value Line Publishing, Inc.
Publication Name: The Value Line Investment Survey (Part 3 - Ratings & Reports)
Subject: Business, general
ISSN: 0042-2401
Year: 2003
Product information, Biotechnology industry, Biotechnology industries, Exelixis Inc.
Publication Name: The Value Line Investment Survey (Part 3 - Ratings & Reports)
Subject: Business, general
ISSN: 0042-2401
Year: 2003
User Contributions:
Comment about this article or add new information about this topic:
Subjects list: United States, Finance, Company investment, Investments, Statistics, Securities, Company sales and earnings, Company earnings/profit, Company securities, Company business forecast/projection, Company forecasts
Similar abstracts:
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.